Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730421 | 0.80 | KDM4E (0.35) | HTR2CHTR2AHTR2BALDH1A1MEN1 | |
| SCHEMBL4403294 | 0.76 | CYP19A1 (0.44) | HTR2AALDH1A1MEN1KMT2A | |
| SCHEMBL10068328 | 0.76 | MEN1 (0.31) | MEN1KMT2ALMNA | |
| SCHEMBL29370901 | 0.72 | KDM1A (0.52) | — | |
| SCHEMBL413013 | 0.72 | KDM1A (0.52) | — | |
| SCHEMBL22209826 | 0.70 | HTR2C (0.36) | TRPM5HTR2CHTR2AHTR2BTRPA1 | |
| SCHEMBL4443404 | 0.68 | — | — | |
| SCHEMBL4403405 | 0.68 | MEN1 (0.39) | HTR2CHTR2AHTR2BALDH1A1MEN1 | |
| SCHEMBL8057369 | 0.66 | DPP4 (0.42) | HTR2CHTR2AHTR2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL4403306 | 0.65 | MTNR1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595359-B2 | Resin composition for forming optical component, molded product, and optical component | MITSUI CHEMICALS, INC. (JP) | 2026-04-07 | — | — | US | disclosed |
| US-12509489-B2 | Oligopeptide | ZEON CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250179232-A1 | RESIN COMPOSITION, MOLDED PRODUCT, AND OPTICAL MEMBER | ZEON CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| WO-2025100415-A1 | CYCLIC OLEFIN RING-OPENED POLYMER, CYCLIC OLEFIN RING-OPENED POLYMER HYDRIDE, RESIN COMPOSITION, AND RESIN MOLDED BODY | 日本ゼオン株式会社 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025084431-A1 | SURFACE TREATMENT AGENT, SURFACE TREATMENT AGENT KIT, SURFACE-MODIFIED MOLDED ARTICLE, AND METHOD FOR PRODUCING SURFACE-MODIFIED MOLDED ARTICLE | 日本ゼオン株式会社 | 2025-04-24 | — | — | WO | disclosed |
| EP-4502076-A1 | RESIN COMPOSITION, MOLDED BODY, AND OPTICAL MEMBER | Zeon Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024203650-A1 | CELL CULTURING CONTAINER | 日本ゼオン株式会社 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024166915-A1 | CELL CULTURE CONTAINER WITH SURFACE MODIFIER LAYER AND PRODUCTION METHOD THEREOF, AND METHOD FOR APPLYING SURFACE MODIFIER SOLUTION | 日本ゼオン株式会社 | 2024-08-15 | — | — | WO | disclosed |
| US-20240199694-A1 | OLIGOPEPTIDE | ZEON CORPORATION (JP) | 2024-06-20 | — | — | US | disclosed |
| WO-2024127881-A1 | CYCLIC OLEFIN RING-OPENED POLYMER HYDRIDE, RESIN COMPOSITION AND FILM | 日本ゼオン株式会社 | 2024-06-20 | — | — | WO | disclosed |
| US-6277923-B1 | WITH VERY LOW CONTENT OF FOREIGN MATTERS, BY FILTERING WITH A ZETA POTENTIAL FILTER; MOLDINGS | NIPPON ZEON CO., LTD (JP) | 2001-08-21 | — | — | US | disclosed |
| EP-1026189-A1 | THERMOPLASTIC DICYCLOPENTADIENE-BASE OPEN-RING POLYMERS, HYDROGENATED DERIVATIVES THEREOF, AND PROCESSES FOR THE PREPARATION OF BOTH | Nippon Zeon Co., Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-1006134-A1 | NORBORNENE POLYMER AND PROCESS FOR THE PREPARATION THEREOF | NIPPON ZEON CO., LTD. (JP) | 2000-06-07 | — | — | EP | disclosed |
| EP-0713893-B1 | HYDROGENATED NORBORNENE-BASE RING-OPENING POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | NIPPON ZEON CO (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0936231-A1 | MODIFIED THERMOPLASTIC NORBORNENE POLYMER AND PROCESS FOR THE PRODUCTION THEREOF | NIPPON ZEON CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0936230-A1 | MODIFIED THERMOPLASTIC NORBORNENE POLYMER AND PROCESS FOR THE PRODUCTION THEREOF | NIPPON ZEON CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0930326-A1 | NORBORNENE POLYMER AND PROCESS FOR PREPARING THE SAME | NIPPON ZEON CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0827975-A2 | Cycloolefin-based polymer and process for producing the same | NIPPON ZEON CO., LTD. (JP) | 1998-03-11 | — | — | EP | disclosed |
| US-5681900-A | Hydrogenated norbornene ring-opening polymerization product, a process for production thereof and uses thereof | NIPPON ZEON CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| EP-0713893-A1 | HYDROGENATED NORBORNENE-BASE RING-OPENING POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | NIPPON ZEON CO., LTD. (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595359-B2 | Resin composition for forming optical component, molded product, and optical component | ASIC1, NLRP1, ASIC3 | TRPM5 329/4885HTR2C 2692/4885HTR2A 2469/4885 |
| US-12509489-B2 | Oligopeptide | FN1, HGF, TNFSF11 | TRPM5 3943/4885HTR2C 2214/4885HTR2A 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.